相关实验视频

Updated: Jul 20, 2025

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

SEC61G帮助EGFR增强型质母细胞瘤逃避免疫消除

Kunlin Zeng¹, Yu Zeng¹, Hongchao Zhan¹

¹Department of Cell Biology, School of Basic Medical Science, Southern Medical University, Guangzhou 510515, China.

Proceedings of the National Academy of Sciences of the United States of America

|July 31, 2023

概括

在质母细胞瘤中与EGFR共同增强的SEC61G通过稳定免疫检查点连接体来驱动免疫逃避. 抑制SEC61G可以增强T细胞活性和EGFR增强型质母细胞瘤的组合疗法.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

质母细胞瘤 (GBM) 中最常见的遗传变异是染色体7p11放大,通常导致表皮生长因子受体 (EGFR) 拷贝数增加.
尽管在50-60%的GBM中存在EGFR放大,但EGFR向疗法在临床上取得了有限的成功,这表明需要了解潜在的耐药性机制.

研究的目的:

调查与EGFR共同增强的基因在GBM病变发生过程中的作用.
确定EGFR增强型质母细胞瘤的新型治疗点,特别关注免疫逃避机制.

主要方法:

在GBM中分析基因共同放大模式.
评估SEC61G表达及其在免疫检查点连接体 (ICL) 处理中的功能.
在实体研究中,小鼠模型中涉及SEC61G枯竭和组合治疗.

主要成果:

SEC61G与EGFR一致共强化,在GBM中高度表达,促进瘤免疫逃避.
作为SEC61转位子的一部分,SEC61G促进了ICLs (PD-L1,PVR,PD-L2) 的转位,糖化和膜呈现.
在小鼠中,SEC61G的枯竭增强了CD8+T细胞的透和活性,抑制了GBM的生长,并增加了EGFR氨酸激酶抑制剂的疗效.

结论:

在EGFR增强型质母细胞瘤中,SEC61G在调解免疫逃避方面发挥着关键作用.
向SEC61G为组合治疗提供了一个有希望的策略,以改善GBM的治疗结果.

关键词:

欧洲农业基金会 (EGFR) 是一个基金.在PD-L1中.美国SEC61G 质母细胞瘤是一种质母细胞瘤.免疫逃避免疫逃避

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...